Event will focus on optimizing integration of
lasers into clinical practice with recognized leaders from
all dental specialties and academia
FOOTHILL
RANCH, Calif., June 9, 2022
/PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the
global leader in dental lasers is proud to host its first annual
meeting of leading dental laser experts on June 10, 2022 and June 11,
2022 at the Avenue of the Arts in Costa Mesa, CA.
The event gathers over 20 renowned clinicians from the general
dentistry community, Endodontics, Periodontics, Pediatrics, Hygiene
and academia. This group is among the leading voices in clinical
care currently utilizing dental lasers and the gathering will
promote faster integration of laser technology into clinical
practice and increased acceptance of lasers in dentistry
globally.
"We are excited to bring leading dentists and hygienists
together to discuss current treatments and accelerating the pace of
laser adoption" commented John
Beaver, President and Chief Executive Officer. "It is
rewarding to see our mission of advancing dentistry being embraced
by so many in the industry, and we look forward to working with
this group of distinguished clinicians to enact further positive
change in patient standard of care."
Sessions include new models for training, immersive education,
dental team and patient communication as well as ideation and new
ways to bring laser technology to the forefront of patient
care.
For more information on the event visit:
https://events.wcli.org/event/c3bccc8f-72e0-4a98-a72b-4226247bd657/summary
About BIOLASE
BIOLASE is a medical device company that develops,
manufactures, markets, and sells laser systems in dentistry and
medicine. BIOLASE's products advance the practice of dentistry and
medicine for patients and healthcare professionals. BIOLASE's
proprietary laser products incorporate approximately 301 patented
and 32 patent-pending technologies designed to provide biologically
and clinically superior performance with less pain and faster
recovery times. BIOLASE's innovative products provide cutting-edge
technology at competitive prices to deliver superior results for
dentists and patients. BIOLASE's principal products are
revolutionary dental laser systems that perform a broad range of
dental procedures, including cosmetic and complex surgical
applications. BIOLASE has sold over 43,300 laser systems
to date in over 80 countries around the world. Laser products under
development address BIOLASE's core dental market and other adjacent
medical and consumer applications.
For updates and information on Waterlase iPlus®, Waterlase
Express™, and laser dentistry, find BIOLASE online at
www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at
www.twitter.com/biolaseinc, Instagram at
www.instagram.com/waterlase_laserdentistry, and LinkedIn at
www.linkedin.com/company/biolase.
BIOLASE®, Waterlase® and Waterlase iPlus® are registered
trademarks of BIOLASE, Inc.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, as that
term is defined in the Private Litigation Reform Act of 1995, that
involve significant risks and uncertainties, including statements
regarding the anticipated roll out of new go-to-market sales
strategies, the Company's efforts to achieve its goal of becoming
EBITDA positive. Forward-looking statements can be identified
through the use of words such as "anticipates," "expects,"
"intends," "plans," "believes," "seeks," "estimates," "may,"
"will," "should," and variations of these words or similar
expressions. Readers are cautioned not to place undue reliance on
these forward-looking statements, which reflect BIOLASE's current
expectations and speak only as of the date of this release. Actual
results may differ materially from BIOLASE's current expectations
depending upon a number of factors. These factors include,
among others, adverse changes in general economic and market
conditions, competitive factors including but not limited to
pricing pressures and new product introductions, uncertainty of
customer acceptance of new product offerings and market changes,
risks associated with managing the growth of the business, and
those other risks and uncertainties that are described, from
time-to-time, in the "Risk Factors" section of BIOLASE's annual
reports filed on Form 10-K with the Securities and Exchange
Commission. Except as required by law, BIOLASE does not undertake
any responsibility to revise or update any forward-looking
statements.
For further information, please contact:
EVC Group LLC
Michael Polyviou / Todd Kehrli
(732) 933-2754
mpolyviou@evcgroup.com / tkehrli@evcgroup.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/biolase-announces-inaugural-clinical-excellence-forum-301564722.html
SOURCE BIOLASE, Inc.